Complete Clearance of Ph+ Metaphases after 3 Months Is a Very Early Indicator of Good Response to Imatinib as Front-Line Treatment in Chronic Myelogenous Leukemia | Citedby Results | Acta Haematologica | Karger Publishers

Skip to Main Content

Skip Nav Destination

Complete Clearance of Ph+ Metaphases after 3 Months Is a Very Early Indicator of Good Response to Imatinib as Front-Line Treatment in Chronic Myelogenous Leukemia

Acta Haematol (2013) 129 (2): 126–134.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Evaluation of Molecular Response to Imatinib Mesylate Treatment in Iranian Patients With Chronic Myeloid Leukemia

Ladan Nekoohesh
Shahrbano Rostami
Mohsen Nikbakht
Saeed Mohammadi
Davood Babakhani
Kamran Alimoghaddam
Mohammad H. Ghahremani
Bahram Chahardouli

Clinical Lymphoma Myeloma and Leukemia (2020) 20 (1): e1.

The predictive value of early molecular response in chronic myeloid leukaemia patients treated with imatinib in a single real-world medical centre in a developing country

PC Bee
V Sekaran
RR Ng
TY Kweh
GG Gan

Singapore Medical Journal (2017) 58 (3): 150.

Can prognostic scoring systems for chronic myeloid leukemia as established in adults be applied to pediatric patients?

David Gurrea Salas
Ingmar Glauche
Josephine T. Tauer
Christian Thiede
Meinolf Suttorp

Annals of Hematology (2015) 94 (8): 1363.